Search
引用資料與參考文獻 (1)
Invitrogen™
LentiArray™ CRISPR Negative Control Lentivirus, human, non-targeting
Negative control gRNAs are essential in screening applications for setting thresholds for hit determination. The Invitrogen™ LentiArray™ CRISPR Negative Control深入閱讀
| 產品號碼 | Quantity |
|---|---|
| A32327 | 1 mL |
產品號碼 A32327
價格 (TWD)
64,050.00
Online offer
Ends: 31-Dec-2025
91,500.00您節省 27,450.00 (30%)
Each
Quantity:
1 mL
價格 (TWD)
64,050.00
Online offer
Ends: 31-Dec-2025
91,500.00您節省 27,450.00 (30%)
Each
Negative control gRNAs are essential in screening applications for setting thresholds for hit determination. The Invitrogen™ LentiArray™ CRISPR Negative Control Lentivirus, Human Scrambled, contains a gRNA sequence with no sequence homology to any region of the human genome.
For Research Use Only. Not for use in diagnostic procedures.
規格
For Use With (Application)Genome Editing
Product LineLentiArray
Product TypegRNA
Quantity1 mL
Shipping ConditionDry Ice
Control TypeNegative Control
FormatTube
RNAi TypegRNA
SpeciesHuman
Unit SizeEach
內容物與存放
1 x 1 mL. Store at -68 to -85°C.
引用資料與參考文獻 (1)
引用資料與參考文獻
Abstract
A functional screening of the kinome identifies the Polo-like kinase 4 as a potential therapeutic target for malignant rhabdoid tumors, and possibly, other embryonal tumors of the brain.
Journal:Pediatr Blood Cancer
PubMed ID:28398638
Malignant rhabdoid tumors (MRTs) are deadly embryonal tumors of the infancy. With poor survival and modest response to available therapies, more effective and less toxic treatments are needed. We hypothesized that a systematic screening of the kinome will reveal kinases that drive rhabdoid tumors and can be targeted by specific